ROBERT W. COLMAN, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Doctors Frank, Gelfand, and Atkinson have presented an impressive NIH Conference on hereditary angioedema (Ann Intern Med 84:580-593, 1976). They indicate that although long-term and short-term prophylaxis of attacks have been successful, specific therapy for acute attacks is not available.
Kininogen, the substrate of kallikrein, is activated and decreases during an attack, (1, 2), suggesting that bradykinin formation may play a role in the pathogenesis of this disease. The mode of release of the C2-kinin (3) released during attacks of hereditary angioedema is not fully known, but the inhibition of its formation by soybean trypsin inhibitor suggests
COLMAN RW. Hereditary Angioedema and Heparin Therapy. Ann Intern Med. ;85:399–400. doi: 10.7326/0003-4819-85-3-399
Download citation file:
Published: Ann Intern Med. 1976;85(3):399-400.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use